<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Almazov National Medical Research Centre</title>
	<atom:link href="https://www.almazovcentre.ru/?cat=206&#038;feed=rss2&#038;lang=en" rel="self" type="application/rss+xml" />
	<link>https://www.almazovcentre.ru?lang=en</link>
	<description>Almazov National Medical Research Centre</description>
	<lastBuildDate>Wed, 18 Nov 2026 13:21:25 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=4.1.1</generator>
	<item>
		<title>Almazov Centre has launched clinical trials of a nitric oxide device made in Russia</title>
		<link>https://www.almazovcentre.ru/?p=61503&#038;lang=en</link>
		<comments>https://www.almazovcentre.ru/?p=61503&#038;lang=en#comments</comments>
		<pubDate>Tue, 06 Aug 2019 08:04:38 +0000</pubDate>
		<dc:creator><![CDATA[Мария Александрова]]></dc:creator>
				<category><![CDATA[]]></category>

		<guid isPermaLink="false">http://www.almazovcentre.ru/?p=61503</guid>
		<description><![CDATA[Almazov Centre is carrying out clinical trials of the Tianox nitric oxide device. The device was developed by Sarov scientists from the Russian Federal Nuclear Centre – All-Russia Research Institute of Experimental Physics (a ROSATOM’s company) and is intended for the production of nitric oxide from atmospheric air and inhaled nitric oxide therapy for various <a href='https://www.almazovcentre.ru/?p=61503&#038;lang=en' class='excerpt-more'>[...]</a>]]></description>
				<content:encoded><![CDATA[<p>Almazov Centre is carrying out clinical trials of the <em>Tianox</em> nitric oxide device.</p>
<p>The device was developed by Sarov scientists from the Russian Federal Nuclear Centre – All-Russia Research Institute of Experimental Physics (a ROSATOM’s company) and is intended for the production of nitric oxide from atmospheric air and inhaled nitric oxide therapy for various diseases in children and adults.</p>
<p><span id="more-61503"></span></p>
<p><img class="alignnone size-full wp-image-57554 rad-border" src="http://www.almazovcentre.ru/wp-content/uploads/1562836879_06_0.jpg" alt="1562836879_06_0" width="1000" height="667" data-id="57554" /></p>
<p>Clinical trials are conducted in accordance with the Order of the Russian Ministry of Health. The medical device of a new type using new unique technologies is tested in humans. The necessary permits were obtained from the Federal Service for Supervision in Healthcare, the Ethics Committee of the Russian Ministry of Health and the local ethics committee of Almazov Centre.</p>
<p>Currently, nitric oxide is generated chemically at stationary sites and delivered to healthcare facilities in pressurized cylinders. It has a number of significant drawbacks: the need for periodic purchase of nitric oxide cylinders, complicated logistics and a limited shelf life of nitric oxide in cylinders.</p>
<p>The <em>Tianox</em> device is able to generate nitric oxide directly from atmospheric air during therapy. It eliminates the use of cylinders and significantly increases the availability of this treatment method in practical medicine.</p>
<blockquote><p>“The device has successfully passed technical tests in the laboratories of Federal Service for Supervision in Healthcare and the Russian Testing and Certification Authority, sanitary-chemical, as well as toxicological tests in accredited centres. The results confirmed that the device meets the requirements for safe use,” explained <strong>Alexander Shirshin</strong>, one of the developers representing the Russian Federal Nuclear Centre – All-Russia Research Institute of Experimental Physics.</p></blockquote>
<p>The developers train doctors to work with the device and monitor the use of the device in real setting.</p>
<p>
<div id="attachment_57570" style="width: 1010px" class="wp-caption alignnone"><img class=" size-full wp-image-57570 rad-border" src="http://www.almazovcentre.ru/wp-content/uploads/05_0_0.jpg" alt="05_0" width="1000" height="667" data-id="57570" />
<p class="wp-caption-text">From left to right: Alexander Shirshin, lead researcher of the Russian Federal Nuclear Centre – All-Russia Research Institute of Experimental Physics, A. Bautin, Head of Anesthesiology and Intensive Care Research Laboratory of Almazov Centre and O. Valdaeva, intensivist</p>
</div>
<blockquote><p>“<em>Tianox</em> implements a unique opportunity for a safe bedside generation of inhaled nitric oxide. Besides, the by-product of therapy, nitrogen dioxide, is removed from nitric oxide. Nitric oxide inhalation is highly effective in the intensive care of critical conditions caused by pulmonary hypertension in children and adults. In these clinical cases, the use of this device can be considered as a life-saving treatment method,” says <strong>Andrey Bautin</strong>, the principal investigator and Head of Anesthesiology and Intensive Care Research Laboratory at Almazov Centre.</p></blockquote>
<p>The device can be used in intensive care units, anesthesiology departments, cardiology centres, neonatal units and perinatal centres. It is protected by five Russian patents.</p>
]]></content:encoded>
			<wfw:commentRss>https://www.almazovcentre.ru/?feed=rss2&#038;p=61503&#038;lang=en</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Making CAR-T cell therapy accessible in Russia</title>
		<link>https://www.almazovcentre.ru/?p=60576&#038;lang=en</link>
		<comments>https://www.almazovcentre.ru/?p=60576&#038;lang=en#comments</comments>
		<pubDate>Mon, 04 Mar 2019 08:15:08 +0000</pubDate>
		<dc:creator><![CDATA[Мария Александрова]]></dc:creator>
				<category><![CDATA[]]></category>

		<guid isPermaLink="false">http://www.almazovcentre.ru/?p=60576</guid>
		<description><![CDATA[Modern medicine is increasingly using the achievements of biotechnology and cell biology to achieve not only longer life expectancy, but also a better quality of life. However, there is a long way to go from the success of fundamental science, in particular, experimental oncology and oncoimmunology, to clinical practice. Many Russian families faced with a <a href='https://www.almazovcentre.ru/?p=60576&#038;lang=en' class='excerpt-more'>[...]</a>]]></description>
				<content:encoded><![CDATA[<p>Modern medicine is increasingly using the achievements of biotechnology and cell biology to achieve not only longer life expectancy, but also a better quality of life. However, there is a long way to go from the success of fundamental science, in particular, experimental oncology and oncoimmunology, to clinical practice. Many Russian families faced with a terrible diagnosis of cancer refuse to perceive it as a death sentence and are looking for accessible research advancements, modern high-quality care and treatment.<br />
<span id="more-60576"></span></p>
<p>Immunotherapy is one of the promising modalities for cancer treatment. It is based on the fact that our own immune system has the ability to prevent the development of cancer. When this immunity is weakened, the anti-tumor control may be impaired. Therefore, the goal of immunotherapy is to use human immune cells to destroy tumor cells. However, activating or reactivating the suppressed antitumor immunity generally requires extensive and expensive high-tech cell manipulations.</p>
<p><img class="alignnone size-full wp-image-54911" src="http://www.almazovcentre.ru/wp-content/uploads/Shutterstock_0.jpg" alt="Shutterstock_0" width="1000" height="750" data-id="54911" /></p>
<p>Cellular immunotherapy, including the FDA-approved CAR-T cell drugs, immune checkpoint inhibitors and cytokine therapy, are the most advanced approaches for cancer treatment. CAR-T cell therapy is one of the most promising breakthroughs. Its principle is simple: T cells can be isolated from human blood, multiplied and genetically modified to recognize the tumor, and thereafter they can be infused into the patient’s blood in the form of a biomedical cell product. This treatment helps the immune system selectively find and destroy tumor cells.</p>
<p>
<div style="width: 178px" class="wp-caption alignright"><a href="http://www.almazovcentre.ru/wp-content/uploads/IMG_3220_0.jpeg"><img id="__wp-temp-img-id" class="rad-border" src="http://www.almazovcentre.ru/wp-content/uploads/IMG_3220_0.jpeg" alt="" width="168" height="242" /></a>
<p class="wp-caption-text">Lymphocytes are stored in liquid nitrogen</p>
</div>
<p>Since the end of 2014, Alexey Petukhov, researcher at Almazov Centre, and his colleagues have been successfully carrying out laboratory preparation and testing of genetically modified anticancer human T-cells (CAR-T). The work is both within the fundamental research domain and in the practical domain and is aimed at developing an affordable and accessible CAR-T cell drug. The main goal of the young scientists at Almazov Centre is to make a shift from words to actions and make the developments accessible for cancer patients.</p>
<p>The specialists of Almazov Centre in St. Petersburg work in several areas in the field of CAR-T: experimental GMP manufacturing process and its own patent portfolio; new options of CAR-T cells; CAR-T cells for solid tumors; allogeneic CAR-T cells; reducing the cost of CAR-T cell therapy and creating CAR-T cell therapy to treat non-cancerous diseases; developing the technology for CAR-T cell manufacture without ex vivo cultivation; the use of genetic editing for cancer treatment; conducting basic research.</p>
<p>Achieving the most complete implementation for these areas and improving the accessibility of high-tech medicine for cancer patients in the country are only possible by the concerted effort of various specialists: doctors, biologists, engineers, biotechnologists, geneticists, and bioinformatists. This can be done within adequately funded genomic centres of global importance. A number of such centres will be established in Russia as part of Science national project and the Federal Programme for the Development of Genetic Technologies for 2019–2027. Almazov Centre is preparing to become a basis for creating and developing such centre jointly with its partners in the “Translational medicine” consortium.</p>
<p>
<div style="width: 252px" class="wp-caption alignright"><a href="http://www.almazovcentre.ru/wp-content/uploads/Фото-6_0.jpg"><img id="__wp-temp-img-id" class="rad-border" src="http://www.almazovcentre.ru/wp-content/uploads/Фото-6_0.jpg" alt="" width="242" height="168" /></a>
<p class="wp-caption-text">Almazov Centre has been carrying out laboratory preparation and testing of genetically modified anticancer human T-cells (CAR-T cells) since 2014</p>
</div>
<p>For successful implementation of the projects, apart from scientific research, the specialists of Almazov Centre focus on the process for manufacturing the components of a CAR-T cell drug, including vectors for genetic modification of T cells that are currently the most expensive and difficult to obtain component.</p>
<p>The unique features of the Centre are the direct communication between doctors and scientists, a clear understanding of certain steps in research, focus on the patient’s needs. The global status of a clinical and research facility will contribute to further development of CAR-T cell technology, its wide availability and practical applicability.</p>
]]></content:encoded>
			<wfw:commentRss>https://www.almazovcentre.ru/?feed=rss2&#038;p=60576&#038;lang=en</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Experience in managing patients with long-term impairment of consciousness at Polenov Neurosurgical Institute, the branch of Almazov Centre</title>
		<link>https://www.almazovcentre.ru/?p=61612&#038;lang=en</link>
		<comments>https://www.almazovcentre.ru/?p=61612&#038;lang=en#comments</comments>
		<pubDate>Thu, 21 Feb 2019 14:25:49 +0000</pubDate>
		<dc:creator><![CDATA[Мария Александрова]]></dc:creator>
				<category><![CDATA[]]></category>

		<guid isPermaLink="false">http://www.almazovcentre.ru/?p=61612</guid>
		<description><![CDATA[The Anesthesiology and Intensive Care Unit of Polenov Neurosurgical Institute was established in the 60s of the last century. The work of this department is based on the fundamental achievements of neurophysiology. Proprietary methods of anesthetic management, neuromonitoring, brain protection against ischemia/hypoxia have been patented and derived from the current understanding of passive-defensive reactions and <a href='https://www.almazovcentre.ru/?p=61612&#038;lang=en' class='excerpt-more'>[...]</a>]]></description>
				<content:encoded><![CDATA[<p>The Anesthesiology and Intensive Care Unit of Polenov Neurosurgical Institute was established in the 60s of the last century. The work of this department is based on the fundamental achievements of neurophysiology. Proprietary methods of anesthetic management, neuromonitoring, brain protection against ischemia/hypoxia have been patented and derived from the current understanding of passive-defensive reactions and sanogenesis mechanisms in severe multiple pathological effects on the brain. <strong>Ekaterina Kondratieva</strong>, neurologist, leading researcher of the Anesthesiology and Intensive Care Unit, tells more about this.<br />
<span id="more-61612"></span></p>
<p>Interesting results, both scientific and practical, were obtained in patients with long-term impairment of consciousness. The pathogenetic analysis of this condition using the current understanding of a steady condition of the central nervous system has proved promising from both scientific and practical viewpoints. Rather effective methods for the examination and treatment of this patient group have been developed and patented.</p>
<p>The standard examination protocol for a patient with a long-term impairment of consciousness includes an assessment using the coma recovery scale and an EEG.</p>
<p>Almazov Centre has state-of-the-art neuroimaging facilities. Positron emission tomography with fluorodeoxyglucose (FDG PET) of the brain is performed in all patients with impaired consciousness. It is the most sensitive method to predict the recovery of consciousness in patients in a vegetative state.</p>
<p>The radiology department plays a major role in identifying the functional reserve for further recovery of consciousness. Brain MRI is performed using the latest techniques – functional MRI, tractography, spectroscopy. A whole team of intensivists and neurologists specializing in certain diagnostic and therapeutic techniques works with the patients in a steady unconscious state.</p>
<p>Our specialists are familiar with all common methods of examining a patient with severe brain damage: ultrasound and Doppler sonography, echocardiography and electroneuromyography used to detect signs of critical illness polyneuropathy. To determine the degree of dysphagia, endoscopic evaluation of swallowing is performed.</p>
<p>Much attention is paid to the study of circadian rhythms and sleep disorders using polysomnography combined with the determination of the release of the sleep hormone melatonin. The Somnology Group, a division of the Arterial Hypertension Research Department, carries out this work.</p>
<p>Both standard and the latest methods are used to treat patients with long-term impairment of consciousness. These include massage, physical therapy and non-invasive brain stimulation techniques such as transcranial magnetic stimulation and transcranial direct current stimulation.</p>
<p>For patients with severe brain injury in the acute period and in some cases of prolonged impairment of consciousness, the cerebral hypothermia method developed by Russian pathophysiologists and intensivists is used.</p>
<p>Over the past 10 years, Polenov Neurosurgical Institute has gained extensive experience in inserting a microcatheter directly into the cavernous segment of the internal carotid artery or into the intracranial segment of the vertebral artery for prolonged injection of drugs improving metabolism and blood supply to the most affected brain regions. A dedicated and highly skilled team of neurosurgeons and anesthesiologists performs planned neurosurgical interventions in patients in a vegetative state, including plastic surgery of the skull and placement of ventriculoperitoneal shunts.</p>
<p>The Anesthesiology and Intensive Care Unit has been developing a comprehensive treatment protocol for contractures and spasticity in patients with long-term impairment of consciousness. Botulinum toxin therapy is used for treatment of spasticity and patients receive ultrasound-guided injections. Contractures are treated using the technique of prolonged peripheral blockade of the brachial plexus trunks with local anesthetic.</p>
<p>A round-the-clock diagnostic laboratory ensures high-quality and reliable test results. In addition to routine laboratory tests, markers of apoptosis and sanogenesis processes are examined in each patient with impaired consciousness.</p>
<p><strong>Clinical cases</strong></p>
<p>Patient A., 44-year-old male: severe brain injury, removal of an epidural hematoma in the left temporoparietal region in January 2018.</p>
<div style="width: 100%; float: left; text-align: center; display: inline-flex;">
<div style="margin: 0 auto;">
<div style="float: left;">
<p>
<div id="attachment_54078" style="width: 210px" class="wp-caption alignnone"><img class=" size-full wp-image-54078 rad-border" src="http://www.almazovcentre.ru/wp-content/uploads/Фото1.-Пациент-А.jpg" alt="Фото1. Пациент А" width="200" height="300" data-id="54078" />
<p class="wp-caption-text">Patient A. in the ICU of Polenov Neurosurgical Institute</p>
</div>
</div>
<div style="float: left;">
<p>
<div id="attachment_54079" style="width: 210px" class="wp-caption alignnone"><img class=" size-full wp-image-54079 rad-border" src="http://www.almazovcentre.ru/wp-content/uploads/Фото2.-Пациент-А.jpg" alt="Фото2. Пациент А" width="200" height="300" data-id="54079" />
<p class="wp-caption-text">Patient A. 12 months after the brain injury</p>
</div>
</div>
</div>
</div>
<p>Patient E., 19-year-old male: consequences of exogenous intoxication of unknown etiology. Admitted to the ICU of Polenov Neurosurgical Institute in a very severe state in March 2018.</p>
<div style="width: 100%; float: left; text-align: center; display: inline-flex;">
<div style="margin: 0 auto;">
<div style="float: left;">
<p>
<div id="attachment_54080" style="width: 210px" class="wp-caption alignnone"><img class=" size-full wp-image-54080 rad-border" src="http://www.almazovcentre.ru/wp-content/uploads/Фото3.-Пациент-Э..jpg" alt="Фото3. Пациент Э." width="200" height="300" data-id="54080" />
<p class="wp-caption-text">Patient E. 2 months after admission. First attempt of breathing through the tracheostomy tube. Tube feeding</p>
</div>
</div>
<div style="float: left;">
<p>
<div id="attachment_54081" style="width: 210px" class="wp-caption alignnone"><img class=" size-full wp-image-54081 rad-border" src="http://www.almazovcentre.ru/wp-content/uploads/Фото-4.jpg" alt="Фото 4" width="200" height="300" data-id="54081" />
<p class="wp-caption-text">3.5 months after admission. First walks around the hospital. Breathing through a tracheostomy tube</p>
</div>
</div>
<div style="float: left;">
<p>
<div id="attachment_54077" style="width: 210px" class="wp-caption alignnone"><img id="__wp-temp-img-id" class=" size-full wp-image-54077 rad-border" src="http://www.almazovcentre.ru/wp-content/uploads/Фото-5.jpg" alt="Фото 5" width="200" height="300" data-id="54077" />
<p class="wp-caption-text">10 months later. The patient discharged home, socially adapted.</p>
</div>
</div>
</div>
</div>
]]></content:encoded>
			<wfw:commentRss>https://www.almazovcentre.ru/?feed=rss2&#038;p=61612&#038;lang=en</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New-generation artificial heart implanted for the first time at Almazov Centre</title>
		<link>https://www.almazovcentre.ru/?p=60586&#038;lang=en</link>
		<comments>https://www.almazovcentre.ru/?p=60586&#038;lang=en#comments</comments>
		<pubDate>Wed, 30 Jan 2019 09:06:04 +0000</pubDate>
		<dc:creator><![CDATA[Мария Александрова]]></dc:creator>
				<category><![CDATA[]]></category>

		<guid isPermaLink="false">http://www.almazovcentre.ru/?p=60586</guid>
		<description><![CDATA[The surgeons of Almazov Centre performed a rare surgery in a young man to implant a new-generation domestic ventricular assist device designed for long-term mechanical support of the left ventricle. A 35-year-old man from Kaliningrad was admitted to Almazov Centre in October 2018 with decompensated chronic heart failure on the background of dilated cardiomyopathy – <a href='https://www.almazovcentre.ru/?p=60586&#038;lang=en' class='excerpt-more'>[...]</a>]]></description>
				<content:encoded><![CDATA[<p>The surgeons of Almazov Centre performed a rare surgery in a young man to implant a new-generation domestic ventricular assist device designed for long-term mechanical support of the left ventricle.</p>
<p>A 35-year-old man from Kaliningrad was admitted to Almazov Centre in October 2018 with decompensated chronic heart failure on the background of dilated cardiomyopathy – the impaired contractile function of the heart muscle (myocardium) with marked dilatation of heart chambers. According to statistics, only 30% of patients with this disease survive the first five years…</p>
<p><span id="more-60586"></span></p>
<p><img class="alignnone size-full wp-image-53484 rad-border" src="http://www.almazovcentre.ru/wp-content/uploads/главное-фото-0.jpeg" alt="главное фото-0" width="1000" height="666" data-id="53484" /></p>
<p>The Centre’s team decided that heart should be transplanted after stabilization of the patient’s condition. In order to compensate heart failure and prepare the patient for the upcoming surgery, they jointly chose the optimal treatment strategy and specialized therapy. The patient was treated by the cardiologist <strong>O. Yaznevich</strong> under the supervision of <strong>M. Bortsova</strong>, head of Cardiology Department No. 8, and <strong>I. Orazmagomedova</strong>, head of Anesthesiology Department with ICU No. 8, jointly with <strong>P. Fedotov</strong>, head of Research Laboratory of High-Tech Treatment Methods for Heart Failure, Prof. <strong>M. Sitnikova</strong>, Head of Heart Failure Research Department, and <strong>O. Moiseeva</strong>, MD, DSc, Director of Heart and Vessels Institute.</p>
<p>
<div style="width: 252px" class="wp-caption alignright"><a href="http://www.almazovcentre.ru/wp-content/uploads/IMG_2066_1-0.jpg"><img id="__wp-temp-img-id" class="rad-border" src="http://www.almazovcentre.ru/wp-content/uploads/IMG_2066_1-0.jpg" alt="" width="242" height="168" /></a>
<p class="wp-caption-text">Prof. M. Gordeev implanted the system</p>
</div>
<p>To correct the parameters of central hemodynamics in case of severely impaired systolic function, the first step was to implant the extracorporeal membrane oxygenation system (ECMO) with left ventricular bypass. In fact, ECMO is similar to cardiopulmonary bypass, but it is with minimally invasive access through femoral arteries and veins. The life-saving surgery was performed by <strong>D. Zverev</strong>, head of Interventional Surgery Research Laboratory. Postoperative treatment and follow-up were under the supervision of <strong>A. Maricheva</strong>, head of Anesthesiology Department with ICU No. 7, and <strong>A. Bautina</strong>, head of Anesthesiology Research Laboratory.</p>
<p>Doctors used ECMO as a temporary measure to stabilize the patient and make a decision on further treatment: waiting for a donor heart or implanting an “artificial” one.</p>
<p>
<div style="width: 252px" class="wp-caption alignright"><a href="http://www.almazovcentre.ru/wp-content/uploads/рис.2-0.jpg"><img id="__wp-temp-img-id" class="rad-border" src="http://www.almazovcentre.ru/wp-content/uploads/рис.2-0.jpg" alt="" width="242" height="168" /></a>
<p class="wp-caption-text">STREAM CARDIO device</p>
</div>
<p>They chose the second option — to implant the new-generation domestic LVAD for long-term support,   STREAM CARDIO. In late December 2018, prof. <strong>M. Gordeev</strong>, director of Cardiac Surgery Clinic, together with cardiac surgeons from Sklifosovsky Research Institute for Emergency Medicine and specialists of device manufacturers performed a very complex surgery to implant the device.</p>
<p>The successful surgery gives the patient a chance to survive until a donor heart becomes available for transplant. The man is recovering, and his physical activity has slightly increased for the first time in a long time.</p>
]]></content:encoded>
			<wfw:commentRss>https://www.almazovcentre.ru/?feed=rss2&#038;p=60586&#038;lang=en</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ITMO University and Almazov Centre scientists have developed a new non-contact method of measuring blood flow in arms</title>
		<link>https://www.almazovcentre.ru/?p=60590&#038;lang=en</link>
		<comments>https://www.almazovcentre.ru/?p=60590&#038;lang=en#comments</comments>
		<pubDate>Tue, 30 Oct 2018 13:36:34 +0000</pubDate>
		<dc:creator><![CDATA[Мария Александрова]]></dc:creator>
				<category><![CDATA[]]></category>

		<guid isPermaLink="false">http://www.almazovcentre.ru/?p=60590</guid>
		<description><![CDATA[A research team from ITMO University and Almazov Centre proposed a new non-contact method for measuring blood flow in the upper limbs. The method is based on video recording of the skin surface under green light measuring the absorption of red blood cells. This helps see how effective the circulatory system and the blood flow <a href='https://www.almazovcentre.ru/?p=60590&#038;lang=en' class='excerpt-more'>[...]</a>]]></description>
				<content:encoded><![CDATA[<p>A research team from ITMO University and Almazov Centre proposed a new non-contact method for measuring blood flow in the upper limbs. The method is based on video recording of the skin surface under green light measuring the absorption of red blood cells. This helps see how effective the circulatory system and the blood flow regulation are. The experimental results showed that the proposed method is as accurate as the traditional one. However, it is easier to use, cheaper and suitable for more patients. The research was published in <em>Biomedical Optics Express.</em></p>
<p><span id="more-60590"></span></p>
<p>Measuring blood flow in the limbs is an important diagnostic indicator. By studying how efficient is the heart in supplying blood to the limbs, we can see whether the cardiovascular system works properly, and evaluate parameters of the blood flow regulation. Today, contact (tensiometric) methods of occlusive plethysmography are used to measure blood flow in the limbs. As a rule, they are based on the registration of changes in the volume or diameter of the limb by filling with blood during venous occlusion.</p>
<p>Occlusion is a way to affect the blood flow when a small pressure on the arm stops venous outflow without disturbing the arterial blood flow. Eventually, it is possible to calculate the blood flow by the increase in the limb volume due to the flow of blood from the heart. However, contact measurement systems can be difficult to configure and use. Besides, contact methods are expensive and require adaptation for each patient.</p>
<p>To overcome the limitations of standard methods, scientists from ITMO University and Almazov Centre have developed a non-contact system for measuring blood flow in the upper limbs. It is based on photoplethysmography. This technique is capable of tracking changes in blood filling of the skin by video recording of green light absorption. When the green light hits a red blood cell, the reflected wave changes its polarization. The camera registers only this altered signal and tracks when it gets most intense. The reason for the increase in light absorption during venous occlusion can be explained by the increase in the number of red blood cells, most likely due to the expansion of small veins in the upper layer of the skin.</p>
<p><img class="alignnone size-full wp-image-51747 rad-border" src="http://www.almazovcentre.ru/wp-content/uploads/фото-9-0.jpg" alt="фото-9-0" width="1000" height="666" data-id="51747" /></p>
<p>To assess the accuracy of measurements with the new system, scientists conducted a series of experiments and compared the values obtained by traditional and new methods. Experimental measurements were performed on healthy volunteers. The signal was recorded during several cycles of venous occlusion. The results of the evaluation of cold stress effect on the functioning of vessels obtained by the new method almost completely coincided with the results of traditional measurements.</p>
<p>“In this research, we used four cameras for non-contact measurements to ensure the registration of the signal from all sides of the hand. This would allow us to detect the heterogeneity of the signal, if it occurs due to the difference in the work of the capillaries in different parts of the skin. We developed special software, ordered and assembled the equipment necessary to synchronize and process the data flow simultaneously from four cameras. But in the course of the study, we saw that the difference was not that great, which means that in the future measurements can be carried out with only one camera,” comments Alexey Kamshilin, specialist of the International Scientific and Technical Centre (Computational Optics, Photonics and Image Visualization) of ITMO University.</p>
<p>The proposed method does not directly measure the total musculocutaneous blood flow. However, the research confirmed that the measurement of skin blood flow is subject to the same regulatory effects as the general blood flow in the limb. The proposed contactless method is as accurate as the traditional one, but it is cheaper, easier to use, suitable for most patients and can be applied not only to the upper but also to the lower limbs without additional optimization. Now, scientists are working to adapt the proposed method for the legs.</p>
<p>The researchers found that by registering a change in the absorption of green colour by the skin during the venous occlusion, it is possible to determine the state of blood flow in its upper layers. Changing the conditions of the experiment influences the tone of blood vessels and affects the speed of the blood flow. This allows assessing the vascular resistance regulation by the nervous system and other control mechanisms. Such changes are observed in a number of diseases associated with damage to nerves and blood vessels.</p>
<blockquote><p>“Our ultimate goal is to create an easy-to-use medical device to assess the blood flow in both upper and lower limbs as the registration of blood flow disorders in the legs has an important additional diagnostic potential. Thus, in diabetes, complications most often affect the skin of the lower limbs. There is even such a thing as “diabetic foot”. The new technique will be of interest to both endocrinologists and vascular surgeons who are engaged in the treatment of varicose veins of the lower limbs, as well as the restoration of blood flow in patients with arterial atherosclerosis. At the same time, many changes in the regulation can be detected early enough for effective prevention and treatment,” notes Oleg Mamontov, researcher of the Research Laboratory for Circulatory Physiology at Almazov Centre.</p></blockquote>
]]></content:encoded>
			<wfw:commentRss>https://www.almazovcentre.ru/?feed=rss2&#038;p=60590&#038;lang=en</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Innovative treatment of lower limb varicose vein disease</title>
		<link>https://www.almazovcentre.ru/?p=60584&#038;lang=en</link>
		<comments>https://www.almazovcentre.ru/?p=60584&#038;lang=en#comments</comments>
		<pubDate>Thu, 12 Jul 2018 09:51:22 +0000</pubDate>
		<dc:creator><![CDATA[Мария Александрова]]></dc:creator>
				<category><![CDATA[]]></category>

		<guid isPermaLink="false">http://www.almazovcentre.ru/?p=60584</guid>
		<description><![CDATA[Lower limb varicose vein disease is a major problem in healthcare worldwide. About 25% of the Russian population suffers from various forms of varicose vein disease, and its prevalence and frequency continue to grow. Having a progressive irreversible course, the disease leads to various manifestations of chronic venous insufficiency, including non-healing venous ulcers and venous <a href='https://www.almazovcentre.ru/?p=60584&#038;lang=en' class='excerpt-more'>[...]</a>]]></description>
				<content:encoded><![CDATA[<p>Lower limb varicose vein disease is a major problem in healthcare worldwide. About 25% of the Russian population suffers from various forms of varicose vein disease, and its prevalence and frequency continue to grow. Having a progressive irreversible course, the disease leads to various manifestations of chronic venous insufficiency, including non-healing venous ulcers and venous thromboembolism. In order to prevent the development of such serious complications, patients are encouraged to start treatment as soon as possible.<br />
<span id="more-60584"></span></p>
<p><strong>Radiofrequency ablation of veins</strong></p>
<p>Radiofrequency ablation is a modern technique of minimally invasive treatment for varicose veins. Our Centre has been successfully using it for several years. This method uses radiofrequency energy supplied through a catheter introduced into the vein lumen. A high-frequency alternating current eliminates negative effects on nerve and muscle tissue. It heats only the venous wall that is in direct contact with the electrode. It is associated with reduced risks of vein wall perforation and thermal injury of the adjacent tissues at the time of the procedure. The procedure is performed on VNUS (USA), Covidien AG system using a Closure FAST ™ catheter with an electrode length of 7 cm. Heating to 120 °C leads to destruction in the vein wall and its occlusion.</p>
<p>Radiofrequency ablation (obliteration) is performed with local anesthesia, no special preparation of the patient is required.  The method can be used at different stages of the disease, including post-thrombotic syndrome of the lower limbs. The only contraindication for thermal obliteration is acute thrombosis of the deep and superficial veins of the affected limb.</p>
<p>The advantages of the method are minimal injury to the surrounding tissues, fast and painless recovery period. Thus, radiofrequency ablation is a highly effective and safe method for the treatment of varicose veins of the lower extremities.</p>
<p><strong>VenaSeal adhesive technology</strong></p>
<p>
<div id="attachment_49787" style="width: 1009px" class="wp-caption alignnone"><img class=" size-full wp-image-49787 rad-border" src="http://www.almazovcentre.ru/wp-content/uploads/VenasealSystem-cropped-for-website-e1531388979394.jpg" alt="VenasealSystem-cropped-for-website" width="999" height="331" data-id="49787" />
<p class="wp-caption-text">Catheter VenaSeal Sapheon Closure System</p>
</div>
<p>Another innovative treatment method for lower limb varicose veins is the adhesive technology <em>VenaSeal Sapheon Closure System</em> of Medthronic. Soon it will performed at the Research Department of Vascular and Interventional Surgery headed by <strong>Dr. Mikhail Chernyavsky</strong>. The procedure involves the placement of a medical-grade cyanoacrylate glue into the varicose veins (large or small saphenous veins) using a special catheter to &laquo;glue&raquo; the affected vein and eliminate the venous reflux without local anesthetics.</p>
<p>In recent years, our colleagues in Europe and the USA have been actively using this method. It has shown high efficacy in the treatment of lower limb varicose veins. In Russia, the <em>VenaSeal</em> technology was registered only a few months ago, and Almazov Centre specialists were among the first in the country to be able to use it in everyday practice.</p>
]]></content:encoded>
			<wfw:commentRss>https://www.almazovcentre.ru/?feed=rss2&#038;p=60584&#038;lang=en</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Spine surgery has become easier thanks to 3D printing</title>
		<link>https://www.almazovcentre.ru/?p=61610&#038;lang=en</link>
		<comments>https://www.almazovcentre.ru/?p=61610&#038;lang=en#comments</comments>
		<pubDate>Thu, 12 Jul 2018 09:02:00 +0000</pubDate>
		<dc:creator><![CDATA[Мария Александрова]]></dc:creator>
				<category><![CDATA[]]></category>

		<guid isPermaLink="false">http://www.almazovcentre.ru/?p=61610</guid>
		<description><![CDATA[Nowadays, 3D technologies have been increasingly used in many fields of medicine. Tests have already been done to produce bone cartilage for the kneecap, nose and ears. Also, scientists are working to make 3D-bioprinted artificial eyeballs. This is difficult, but if successful, it will become possible to restore vision to blind people. All evidence suggests, <a href='https://www.almazovcentre.ru/?p=61610&#038;lang=en' class='excerpt-more'>[...]</a>]]></description>
				<content:encoded><![CDATA[<p>Nowadays, 3D technologies have been increasingly used in many fields of medicine. Tests have already been done to produce bone cartilage for the kneecap, nose and ears. Also, scientists are working to make 3D-bioprinted artificial eyeballs. This is difficult, but if successful, it will become possible to restore vision to blind people. All evidence suggests, that soon 3D bioprinters will be capable of printing whole cells from human organ stem cells.<br />
<span id="more-61610"></span></p>
<p>
<div id="attachment_49782" style="width: 1010px" class="wp-caption alignnone"><img class=" size-full wp-image-49782 rad-border" src="http://www.almazovcentre.ru/wp-content/uploads/168.jpg" alt="1" width="1000" height="667" data-id="49782" />
<p class="wp-caption-text">Roman Kovalenko, neurosurgeon</p>
</div>
<p>But there’s more. 3D technologies can be used in many more ways. They can help doctors create excellent tools to perform complex medical procedures and even surgery.</p>
<p>Recently, <strong>Roman Kovalenko</strong>, a neurosurgeon from Almazov Centre, won the best research paper contest held among young neurosurgeons, neurologists, neuroradiologists and other neurology physicians with an article “Using personalized 3D-printed navigation templates for transpedicular screw fixation in the cervical spine: the results of a prospective two-center pilot study”.</p>
<p>Today, often with spinal disorders, neurosurgeons have to resort to surgery when special screw systems are inserted into the vertebrae of a patient. Since vascular and neural structures are located very close to the vertebrae, implants should be inserted with high precision and on a preset path. In some cases, it is quite difficult. For example, in scoliotic deformities, congenital anomalies and neoplastic lesions the anatomical structure of the vertebrae can be changed. It leads to the risks of complications in the insertion of screws (e.g. damage to arterial structures).</p>
<p>One of the classic techniques used by surgeons to improve the accuracy and safety of implantation is an intraoperative x-ray. However sometimes an x-ray projection is not enough for surgeons, they need to see a three-dimensional image in order to properly implant the screw. Until recently, a more accurate navigational method was the use of intraoperative CT and navigation system. CT is performed on the patient during the surgery. The images are then linked to a navigation system, and the surgeon uses this special navigation. This increases the quality of implantation and reduces the rate of complications. This equipment is quite expensive, and the patient is exposed to a large radiation load during surgery.</p>
<p>In his article, Roman Kovalenko described an alternative method for the precise introduction of fixation screws into the spine.</p>
<p>
<div id="attachment_49783" style="width: 1010px" class="wp-caption alignnone"><img class=" size-full wp-image-49783 rad-border" src="http://www.almazovcentre.ru/wp-content/uploads/243-e1531385894920.jpg" alt="2" width="1000" height="729" data-id="49783" />
<p class="wp-caption-text">Vertebra model and 3D-printed navigation template</p>
</div>
<p>The method is based on the use of 3D-printed templates fitting with the patient&#39;s vertebra to ensure the perfect insertion of screws. The rapid prototyping technique (3D printing) has recently been broadly introduced in various areas of surgery.</p>
<blockquote><p>“The method enables precise fixation of screws in cervical spine surgeries, thus reducing the rate of complications and the burden of repeated surgery. Other advantages are the significant reduction of radiation load on the patient (since there is no need for images in different projections), ease of use and relatively low cost. This is a very efficient solution,” the neurosurgeon noted.</p></blockquote>
<p>On the initiative of Roman Kovalenko, this technique is now used in two Russian centres: Almazov Centre and Vreden Russian Research Institute of Traumatology and Orthopedics. The neurosurgeons of Almazov Centre began to use this method in October 2017. Over this time, the surgery has been performed in 26 patients.</p>
]]></content:encoded>
			<wfw:commentRss>https://www.almazovcentre.ru/?feed=rss2&#038;p=61610&#038;lang=en</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Cell therapy of leukemia and lymphomas</title>
		<link>https://www.almazovcentre.ru/?p=61474&#038;lang=en</link>
		<comments>https://www.almazovcentre.ru/?p=61474&#038;lang=en#comments</comments>
		<pubDate>Mon, 11 Dec 2017 12:03:53 +0000</pubDate>
		<dc:creator><![CDATA[Мария Александрова]]></dc:creator>
				<category><![CDATA[]]></category>

		<guid isPermaLink="false">http://www.almazovcentre.ru/?p=61474</guid>
		<description><![CDATA[The idea of using immunity mechanisms to fight malignant diseases has been around for more than a hundred years now. It has long been known that there are special cells in the human body – T lymphocytes, NK cells and macrophages – which are able to recognize and destroy pathologically altered tumor cells. For a <a href='https://www.almazovcentre.ru/?p=61474&#038;lang=en' class='excerpt-more'>[...]</a>]]></description>
				<content:encoded><![CDATA[<p style="text-align: justify;">The idea of using immunity mechanisms to fight malignant diseases has been around for more than a hundred years now. It has long been known that there are special cells in the human body – T lymphocytes, NK cells and macrophages – which are able to recognize and destroy pathologically altered tumor cells.<br />
<span id="more-61474"></span></p>
<p>For a long time, scientists have tried to understand why antitumor immunity did not work well enough and tried to find ways to strengthen it. In recent years, it has become clear that many tumors have mechanisms protecting them against the effects of cells of the immune system and that malignant cells differ little in their immunological properties from normal cells, making it difficult for the immune cells to recognize them. The first problem was partially solved with the appearance of inhibitors, the so-called control points-proteins, by which tumor cells suppress the activation of T lymphocytes. One of such protein is PD-L1. PD-1/PD-L1 inhibitors revolutionized the treatment of patients with intractable skin tumor – melanoma. However, this approach has not been effective in treating all types of tumors.</p>
<p>The development of CAR T cells – one of the types of cell therapy, which combines the latest advancement of molecular biology, genetic engineering and biotechnology – helps in making tumor cells more visible to the immune system.</p>
<p style="text-align: justify;">CAR T (chimeric antigen receptor-T) cells are patient&#39;s T lymphocytes isolated from their own blood, genetically modified and then multiplied many times in sterile laboratory conditions. As a result of genetic modification, the cells (T lymphocytes) begin to produce an artificial protein (chimeric antigen receptor), which has an affinity for a specific target protein (antigen) on the surface of tumor cells. With the help of chimeric antigen receptors, T lymphocytes acquire the ability to recognize tumor cells and selectively attack them. One CAR T cell may in turn destroy some tumor cells. Moreover, the CAR T cells after activation, divide, resulting in the increase of the number of the CAR T cells in the blood, that is to say, there is an amplification of the antitumor effect. Some CAR T cells can persist in the patient&#39;s body for more than a year providing reliable antitumor immunity – protection against recurrence of the disease.</p>
<p style="text-align: justify;">Currently, the most widespread cell therapy involves the use of CAR T cells with different types of CD19 protein receptors, marking tumor cells which originated from B lymphocytes and their predecessors (B-acute lymphoblastic leukemia, B-cell non-Hodgkin&#39;s lymphomas, chronic lymphocytic leukemia). It was observed in clinical studies that more than half of the patients with chemorefractory variants of these diseases after a single intravenous transfusion of CD19-specific CAR T cells had a long deep remission. At the end of 2017, two types of CD19 CAR T therapy (drugs Kymriah and Yescarta) were first approved for clinical use, however, so far only in the United States.</p>
<p style="text-align: justify;"><img class=" rad-border alignright wp-image-44453" src="http://www.almazovcentre.ru/wp-content/uploads/IMG_5544.jpg" alt="" width="317" height="211" data-id="44453" />In Russia, the results of preclinical (in vitro) studies of CD19 CAR T cells were demonstrated for the first time by the specialists of the Institute of Hematology at Almazov Centre on October 26, 2017 at the 14<sup>th</sup> conference <em>Malignant Lymphomas</em> held in Moscow. The poster “Anti-CD19 CAR-T: the experience in obtaining and initial testing of the product” aroused great interest and was awarded a diploma of the third degree. The poster presented the characteristics of CAR T cells with real therapeutic potential, their ability to destroy CD19-positive cells in vitro, and the ability to divide and secrete biologically active substances (IL-2, TNF, IFNy).</p>
<p style="text-align: justify;">At present, Almazov Centre continues to develop this method of therapy, conduct research aimed at obtaining universal allogeneic CAR T cells and study the resistance mechanisms of other tumors to CAR-T therapy.</p>
]]></content:encoded>
			<wfw:commentRss>https://www.almazovcentre.ru/?feed=rss2&#038;p=61474&#038;lang=en</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Vascular surgeons of the Almazov National Medical Research Centre saved the patients with a giant abdominal aorta aneurysm and a complicated «hourglass» aneurysm</title>
		<link>https://www.almazovcentre.ru/?p=61620&#038;lang=en</link>
		<comments>https://www.almazovcentre.ru/?p=61620&#038;lang=en#comments</comments>
		<pubDate>Tue, 02 May 2017 13:23:33 +0000</pubDate>
		<dc:creator><![CDATA[Мария Александрова]]></dc:creator>
				<category><![CDATA[]]></category>

		<guid isPermaLink="false">http://www.almazovcentre.ru/?p=61620</guid>
		<description><![CDATA[In April, 2017, the vascular surgeons under the supervision of the Head of the Vascular and Interventional Surgery Department, Dr. Mikhail Chernyavsky, performed endoprosthesis replacement of aorta in two patients. One of them had a giant aneurysm of the abdominal aorta of 10 cm in size, while the other had an aneurysm of a complicated <a href='https://www.almazovcentre.ru/?p=61620&#038;lang=en' class='excerpt-more'>[...]</a>]]></description>
				<content:encoded><![CDATA[<p style="text-align: justify;">In April, 2017, the vascular surgeons under the supervision of the Head of the Vascular and Interventional Surgery Department, Dr. Mikhail Chernyavsky, performed endoprosthesis replacement of aorta in two patients. One of them had a giant aneurysm of the abdominal aorta of 10 cm in size, while the other had an aneurysm of a complicated topographic anatomy in the form of an hourglass extending to the iliac arteries.<br />
<span id="more-61620"></span></p>
<p>The patients’ state was confounded by the main disease, concomitant pathology and extremely high risk of postoperative complications in case of open surgical interventions. With the endovascular modern bifurcation stent grafts the Almazov Centre doctors achieved 100% percent aneurysms exclusion of the blood stream and saved the patients from aneurism rupture and internal bleeding.</p>
<p style="text-align: justify;">This innovative technique allows avoiding disability of patients, significantly reduces the time of their stay in the clinic and the terms of rehabilitation, as well as improves the quality of life and life expectancy. The doctors of the Vascular and Interventional Surgery Department of the Almazov National Medical Research Centre introduced the minimally invasive reconstructive surgeries in the lesions of peripheral arteries, abdominal aorta aneurysms and descending thoracic aorta into daily clinical practice.</p>
<p><img id="__wp-temp-img-id" class="rad-border alignnone" src="http://www.almazovcentre.ru/wp-content/uploads/IMG_99186.jpg" alt="" width="900" height="507" /></p>
]]></content:encoded>
			<wfw:commentRss>https://www.almazovcentre.ru/?feed=rss2&#038;p=61620&#038;lang=en</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biobank: the link between donors, science and clinical practice</title>
		<link>https://www.almazovcentre.ru/?p=61468&#038;lang=en</link>
		<comments>https://www.almazovcentre.ru/?p=61468&#038;lang=en#comments</comments>
		<pubDate>Fri, 17 Oct 2014 12:50:29 +0000</pubDate>
		<dc:creator><![CDATA[Мария Александрова]]></dc:creator>
				<category><![CDATA[]]></category>

		<guid isPermaLink="false">http://www.almazovcentre.ru/?p=61468</guid>
		<description><![CDATA[Today, one of priorities for Almazov Centre is the work on personalized and translational medicine in the Centre, in St. Petersburg and in Russia. Translational medicine is a fast transfer of basic research results (mainly in the field of cell and molecular biology and biochemistry) into clinical practice, i.e. the creation of diagnostic protocol or <a href='https://www.almazovcentre.ru/?p=61468&#038;lang=en' class='excerpt-more'>[...]</a>]]></description>
				<content:encoded><![CDATA[<p style="text-align: justify;">Today, one of priorities for Almazov Centre is the work on personalized and translational medicine in the Centre, in St. Petersburg and in Russia. Translational medicine is a fast transfer of basic research results (mainly in the field of cell and molecular biology and biochemistry) into clinical practice, i.e. the creation of diagnostic protocol or therapeutic treatment target based on the identified molecular-cellular mechanisms of disease pathogenesis. The aim of personalized medicine is to create diagnostic algorithms and treatment strategy taking into account patient’s individual (genetic) characteristics. Today, these types of clinical practice include molecular diagnostics and pharmacogenetics.</p>
<p style="text-align: justify;"><span id="more-61468"></span></p>
<p style="text-align: justify;"><img class="rad-border alignleft" src="http://www.almazovcentre.ru/wp-content/uploads/biobank1.jpg" alt="" width="359" height="241" /></p>
<p>Usually a lot of time of any biomedical research is spent on research, collection and routine characterization of biological material. To reduce this time, there are biobanks providing biologists and physicians with biological material from patients with specific diseases, as well as from healthy donors by taking a huge amount of work to collect and classify biological samples and the associated clinical information. This ultimately reduces the time for research work and promotes rapid implementation of research results into clinical practice. Consequently, the cost of a newly developed drug or medical technology is also reduced. Thus, biobanks serve as the link between donors of biological material (blood samples, bone marrow, etc.) and academic staff research units, processing and storing the resulting material for later use. In general, biobank is a key instrument of personalized medicine progress and development of drugs as a whole. The key advantages of the biobanks network are the identification of gene function, gene link with diseases, the identification of new therapeutic targets, and validation of the disease biomarkers.</p>
<p style="text-align: justify;">In 2012, the first biobank appeared in our country based on Almazov Centre. The term “biobank” means the storage of biological material samples and associated clinical information intended for biomedical research. The difference between biobank and the collection of biological samples is in the following:</p>
<ul>
<li>systematic clinical information associated with each biological sample,</li>
<li>continuity of storage and samples,</li>
<li>independence of the collection, systematization and storage of biological samples from a particular study,</li>
<li>availability of the biomaterial stored in a biobank for any research group.</li>
</ul>
<p style="text-align: justify;">Biobank of Almazov Centre now actively works on population bio banking of rare clinical cases. Many samples and collections in the biobank are unique in their kind. Today, in the biobank we collected a huge database of characterized and clinically described biological samples from patients with various diseases and healthy donors:</p>
<p style="text-align: justify;"><img class="alignright rad-border" src="http://www.almazovcentre.ru/wp-content/uploads/7501.jpg" alt="" width="360" height="240" /></p>
<ul>
<li>Frozen whole blood — more than 6 thousand samples</li>
<li>Serum — more than 6 thousand samples</li>
<li>Blood plasma — more than a thousand samples</li>
<li>Leukocyte fraction of peripheral blood — more than 500 samples</li>
<li>Mononuclear fraction of bone marrow — about 500 samples</li>
<li>Solid bone marrow — more than 400 samples</li>
<li>Spinal canal and bone marrow smears</li>
<li>Immediately frozen tissue fragments</li>
<li>DNA samples — more than 500 samples</li>
<li>RNA stabilized whole blood</li>
<li>Culture of mesenchymal and hematopoietic stem cells</li>
<li>Samples of urine, saliva, cerebrospinal fluid, etc.</li>
</ul>
<p>The entire amount of biological material is available for experimental studies, both within the research projects of the Centre and external research organizations, such as biomedical research institutions, pharmaceutical and biotechnology companies as this is a prerequisite for the development of translational medicine.</p>
<p style="text-align: justify;">During two years of its existence, the Biobank of Almazov Centre has gained a particular relevance in the development of basic medical science and practical medicine in St. Petersburg.</p>
]]></content:encoded>
			<wfw:commentRss>https://www.almazovcentre.ru/?feed=rss2&#038;p=61468&#038;lang=en</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
